---
title: "Morning Trend | GIANT BIOGENE Bullish Confidence Wavers, Key Support at Risk?"
description: "On January 27th, GIANT BIOGENE (2367.HK) experienced weak fluctuations during the trading session, repeatedly testing the support at the 28 yuan mark without success. Throughout the day, funds continu"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273814399.md"
published_at: "2026-01-28T01:00:00.000Z"
---

# Morning Trend | GIANT BIOGENE Bullish Confidence Wavers, Key Support at Risk?

> On January 27th, GIANT BIOGENE (2367.HK) experienced weak fluctuations during the trading session, repeatedly testing the support at the 28 yuan mark without success. Throughout the day, funds continued to flow out, with a high proportion of trading occurring in the red, indicating a gradual loss of confidence among bulls, and the main positions began to loosen. The biotechnology sector has shown continued weakness over the past week due to differences in local policies. The sector's funds are extremely cautious, lacking leadership from major companies, making it difficult to ignite a bullish atmosphere in the short term. GIANT BIOGENE has not released any significant announcements recently, and the valuation support story struggles to attract new followers. The overall industry sentiment is low, with funds only able to switch between localized hotspots, leading to a further contraction in risk appetite. 

Technically, indicators such as MACD, KDJ, and RSI have all weakened, and a clear downward channel has formed on the daily chart. Although there have been occasional attempts by the main players to bottom-fish in the short term, there are no signs of an overall trend reversal, with the dominance of funds leaning more towards the bears. If there are active large orders that can reverse the trend in the intraday session, there may be a turning point; otherwise, the weak consolidation is likely to continue. 

In summary, GIANT BIOGENE is currently in a phase of dissipating bullish confidence. If the key support level of 28 yuan is breached, it may trigger a new round of technical sell-off. It is recommended that investors focus on position control, wait for unusual fund movements and intraday improvement signals, and avoid blindly betting on a rebound from the left side

On January 27th, GIANT BIOGENE (2367.HK) experienced weak fluctuations during the trading session, repeatedly testing the support at the 28 yuan level without success. Throughout the day, funds continued to flow out, with a high proportion of trading occurring in the red, indicating that bullish confidence is gradually weakening, and the main positions are starting to loosen.

The biotechnology sector has shown continued weakness over the past week due to differences in local policies. Funds in the sector are extremely cautious, lacking a leading company to drive momentum, making it difficult to ignite a bullish atmosphere in the short term. GIANT BIOGENE has not released any significant announcements recently, and the valuation support story struggles to attract new followers. The overall industry sentiment is low, with funds only able to switch between localized hotspots, leading to a further contraction in risk appetite.

From a technical perspective, indicators such as MACD, KDJ, and RSI have all weakened, and a clear downward channel has formed on the daily chart. Although there have been occasional attempts by the main players to bottom-fish in the short term, there are no signs of an overall trend reversal, with control of funds leaning more towards the bears. If there are active large orders that can reverse the trend in the intraday session, there may be a turning point; otherwise, the weak consolidation is likely to continue.

In summary, GIANT BIOGENE is currently in a phase of dissipating bullish confidence. If the key support level of 28 yuan is breached, it may trigger a new round of technical sell-off. It is recommended that investors focus on position control, wait for unusual fund movements and intraday improvement signals, and avoid blindly betting on a rebound from the left side

### Related Stocks

- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [02367.HK - GIANT BIOGENE](https://longbridge.com/en/quote/02367.HK.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md)
- [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盘趋势｜巨子生物多头信心松动，关键支撑岌岌可危？ | 1 月 27 日，巨子生物（2367.HK）盘中弱势震荡，盘面反复探底，多次试探 28 元整数关口支撑未果。全天资金持续流出，绿盘成交占比高，显示多头信心逐步松动，主力持仓筹码开始松懈。 生物科技板块过去一周受地方政策分歧影响，持续表现低迷 | [Link](https://longbridge.com/en/news/273815223.md) |
| 埃隆·马斯克的 Neuralink 在中国激发了脑机接口技术的竞赛 | Neuralink，由埃隆·马斯克创立，正在推动中国脑机接口（BCI）发展的热潮，像 NeuroXess 这样的初创公司迅速进入人体试验阶段。NeuroXess 于 2021 年成立，已经在患者身上测试植入物。中国政府已将 BCI 列为战略 | [Link](https://longbridge.com/en/news/276460367.md) |
| 去年第四季国内批发贸易微跌 1.1% \| 联合早报网 | 新加坡去年第四季国内批发贸易指数同比下滑 1.1%，扭转了前一季的 0.6% 增长。若不包括石油贸易，销售额则上涨 1.1%。各细分领域表现不一，生活用品和家具的批发贸易跌幅最大，达 17.9%；而一般批发贸易同比增幅最大，达 27.7%。 | [Link](https://longbridge.com/en/news/276412225.md) |
| 3.5 亿首付款、总额达 85 亿美元！信达生物与礼来合作布局肿瘤免疫新药研发 | 信达生物与礼来达成突破性合作，将联合开发肿瘤及免疫新药。此次交易预付款 3.5 亿美元，总额最高达 85 亿美元。双方摒弃传统授权，采用从零开始的共同研发模式，标志着中国药企创新力获全球顶尖药企深度认可，开启全球战略协作新篇章。 | [Link](https://longbridge.com/en/news/275269682.md) |
| Neurogan Health 启动独立的补充剂测试计划，以提高不受监管市场的透明度 | Neurogan Health 推出了一项独立的补充剂测试计划，旨在提高补充剂市场的透明度。该项目邀请消费者提交多达 1,000 种产品进行效力和纯度测试，以便验证标签声明。此举解决了在快速增长且监管不足的行业中对产品质量缺乏保障的问题。参 | [Link](https://longbridge.com/en/news/276131094.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
